Equities

Odi Pharma AB (publ)

Odi Pharma AB (publ)

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (SEK)5.00
  • Today's Change1.84 / 58.23%
  • Shares traded105.00
  • 1 Year change-17.36%
  • Beta0.4685
Data delayed at least 15 minutes, as of Sep 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Odi Pharma AB (publ) is a Swedish-based pharmaceutical company. The Company is a manufacturer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. The Company is located in Stockholm.

  • Revenue in SEK (TTM)22.45m
  • Net income in SEK355.97k
  • Incorporated2019
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cyxone AB0.00-22.16m12.56m3.00--0.2684-----0.1388-0.13880.000.12480.00----0.00-59.57-63.71-66.38-69.40------------0.0157------45.87---13.31--
XP Chemistries AB393.54k-7.43m17.89m2.00--0.5219--45.46-0.2059-0.20590.00660.23570.01593.013.45196,770.00-29.91---31.74---1,218.83---1,887.54--3.76--0.00---37.14---1.55------
Lipigon Pharmaceuticals AB9.33m-20.25m24.03m----0.9519--2.58-0.3541-0.35410.10120.17020.2851--0.7439---61.91-314.67-76.67-426.49-----217.15-488.14----0.00----444.4467.83------
Ziccum AB5.56m-23.18m37.82m10.00--4.46--6.81-1.63-1.630.39030.53120.2749--3.31694,500.00-114.67-68.51-163.12-76.47-----417.19-2,598.03----0.0654----75.2025.62---13.45--
StenoCare A/S4.90m-26.36m40.90m9.00--1.27--8.34-1.04-1.040.18681.010.0948--2.07---50.98-28.16-68.69-35.47-----537.63-371.060.6143-6.070.2763---16.30---7.77------
QUIA PHARMA AB (publ)2.36m-13.86m41.72m8.00--1.20--17.68-2.02-2.020.01190.02330.0703--21.36---41.30-95.67-50.35-207.86160.51262.59-587.29-5,002.50---46.790.00------17.75--47.06--
Odi Pharma AB (publ)22.45m355.97k48.10m--135.1021.69134.002.140.02340.02341.470.14572.1954.425.47--3.48-35.0814.86-44.272.07--1.59-99.251.221.81----15,995.75--105.16------
Arctic Bioscience AS30.69m-47.25m51.55m20.00--0.2245--1.68-1.91-1.911.249.270.10570.6742.251,570,792.00-16.27---18.44--29.20---153.95--1.21--0.0075---1.52---33.77------
ExpreS2ion Biotech Holding AB8.10m-45.37m56.71m18.00--0.629--7.00-29.54-29.545.4742.930.0772--6.46311,461.50-43.23-63.54-56.21-75.88-123.56-1.94-560.27-524.31----0.0065--43.07-0.156122.94--19.90--
Elicera Therapeutics AB12.07m-20.79m69.31m2.00--2.68--5.74-0.9137-0.91370.50590.73770.3224--12.856,035,610.00-55.51-40.06-79.82-49.74-----172.21-415.41----0.00--777.23--15.64------
Oncozenge AB0.00-11.78m107.88m----7.59-----1.01-1.010.001.210.00-------55.08---59.44-------------2,944.500.00------65.91------
Lipidor AB87.00k-13.53m113.88m----6.77--1,308.93-0.1505-0.15050.00090.02070.005--0.1843---77.12-59.41-178.11-75.10-----15,550.58-643.36----0.00--73.33-20.3372.24------
Data as of Sep 13 2024. Currency figures normalised to Odi Pharma AB (publ)'s reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.